作为阻塞性睡眠呼吸暂停的P2X3受体对抗剂治疗的Gefapixant:一个随机对照试验
Jonathan A Robbins1, Scott Sands2, Lata Maganti1
1Merck & Co., Inc., Rahway, New Jersey.
概括
吉法皮克松 (Gefapixant) 并没有降低过敏化学反射患者的阻塞性睡眠呼吸暂停 (OSA) 严重程度. P2X3受体对手也增加了夜间低氧症,这表明它.
科学领域:
- 睡眠医学 睡眠医学
- 呼吸系统生理学 呼吸系统生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种普遍存在的疾病,治疗选择有限.
- 过敏化学反射控制呼吸是OSA患者的一个子集的关键机制.
- 目前,没有批准的治疗方法针对这种特定的内型特征.
研究的目的:
- 调查P2X3受体对抗剂fefapixant是否可以降低OSA的严重程度.
- 为了确定fefapixant是否减轻化学反射依赖于化学反射的OSA患者的过敏性心血管化学反射.
主要方法:
- 一项随机的,安慰剂控制的交叉研究,涉及24名中度至重度OSA患者.
- 患者在睡觉前口服Fefapixant 180 mg或安慰剂7天.
- 过夜的多睡眠记录被用来评估呼吸暂停-呼吸暂停指数 (AHI).
主要成果:
- 与安慰剂相比,格法皮克桑并没有显著降低AHI (比率0.92).
- 夜间低氧症在使用fefapixant时显著增加 (比率为2.08).
- 常见的不良事件包括味觉障碍和恶心.
结论:
- 格法皮克桑在降低化学反应依赖性OSA患者的OSA严重性的有效性没有被证明.
- P2X3受体对抗性不太可能成为OSA的可行的治疗策略.
- 格法皮克桑 (Gefapixant) 一般耐受良好,但对OSA严重程度没有提供临床益处.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
141
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
141
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
149
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
149
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
163
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
163
01:19Management of Insomnia
239
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
239
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152